
|Videos|November 17, 2018
Rationale for the Strong Response to Immunotherapy in Melanoma
Author(s)Hussein A. Tawbi, MD, PhD
Hussein A. Tawbi, MD, PhD, discusses why melanoma responds so well to immunotherapy.
Advertisement
Hussein A. Tawbi, MD, PhD, director of Melanoma Clinical Research and Early Drug Development in the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses why melanoma responds so well to immunotherapy.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5








































